CAVTHYSTA
Live / Allowed — Published for opposition (as of 17 Mar 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 29 Aug 2022 filing date already counts against anyone who files later.
Record
- Serial number
- 97569457
- Mark type
- Stylized text
- Filed
- 29 Aug 2022
- Published for opposition
- 17 Mar 2026
- Attorney of record
- Cara M. Kearney
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations and substances for use in oncology; Pharmaceutical preparations and substances for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, neurological, gastrointestinal and immune systems; Pharmaceutical preparations and substances for the treatment of infection, inflammation, hematological, autoimmune related diseases and disorders; Pharmaceutical preparations and substances, namely, antibodies; vaccines
Owner
- AstraZeneca AB, Södertälje, SE
- AstraZeneca AB, Södertälje, SE
Prosecution history
- 17 Mar 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 17 Mar 2026 — PUBLISHED FOR OPPOSITION
- 11 Mar 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 10 Jan 2025 — REINSTATEMENT GRANTED - REQUEST TO DELETE 1(B) FILED
- 10 Jan 2025 — ASSIGNED TO PETITION STAFF
- 02 Dec 2024 — TEAS REQUEST FOR REINSTATEMENT
- 02 Dec 2024 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 02 Dec 2024 — ABANDONMENT - NO USE STATEMENT FILED
- 08 Oct 2024 — TEAS DELETE 1(B) BASIS RECEIVED
- 30 Apr 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 05 Mar 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 05 Mar 2024 — PUBLISHED FOR OPPOSITION
- 14 Feb 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 14 Feb 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 26 Jan 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER